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Abstract
OBJECTIVES: Lung volume reduction surgery (LVRS) improves dyspnoea, quality of life and may even prolong survival in carefully selected
patients with end-stage emphysema. The beneﬁt may be sustained for several years and vanishes with the natural progression of the
disease. Data on repeated surgical treatment of emphysema are scarce. The aim of this study was to evaluate the safety, effects and out-
comes of repeated LVRS (Re-LVRS) in patients no longer beneﬁting from their initial LVRS.
METHODS: Between June 2002 and December 2013, 22 patients (9 females) with advanced emphysema underwent Re-LVRS at a median
of 60 months (25–196) after their initial LVRS. While initial LVRS was performed thoracoscopically as a bilateral procedure, Re-LVRS was
performed unilaterally by a video-assisted thoracoscopic technique in 19 patients and, due to adhesions, by thoracotomy in 3 patients.
Pulmonary function test (PFT) was performed at 3 and 12 months postoperatively.
RESULTS: Lung function at Re-LVRS was similar to that prior to the ﬁrst LVRS. The 90-day mortality rate was 0%. The ﬁrst patient died 15
months postoperatively. The median hospitalization time after Re-LVRS was signiﬁcantly longer compared with the initial LVRS [14 days,
interquartile range (IQR): 11–19, vs 9 days, IQR: 8–14; P = 0.017]. The most frequent complication was prolonged air leak with a median
drainage time of 11 days (IQR: 6–13); reoperations due to persistent air leak were necessary in 7 patients (32%). Five patients (23%) had no
complications. Lung function and Medical Research Council (MRC) score improved signiﬁcantly for up to 12 months after Re-LVRS, with
results similar to those after initial bilateral LVRS. The average increase in the forced expiratory volume in 1 s (FEV1) was 25% (a 7% increase
over the predicted value or 0.18 l) at 3 months, and the mean reduction in hyperinﬂation, assessed by relative decrease in RV/TLC (residual
volume/total lung capacity), was 12% at 3 months (a decrease of 8% in absolute ratios). The mean MRC breathlessness score decreased sig-
niﬁcantly after 3 months (from 3.7 to 2.2).
CONCLUSIONS: Re-LVRS can be performed successfully in carefully selected patients as a palliative treatment. It may be performed as a
bridge to transplantation or in patients with newly diagnosed intrapulmonary nodules or during elective cardiac surgery. Morbidity is
acceptable and outcomes may be satisfactory with signiﬁcantly improved lung function and reduced dyspnoea for at least 12 months
postoperatively.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a leading global
health problem and is predicted to be the third largest cause of
death worldwide by 2020 [1]. It leads to emphysematous destruc-
tion of the lung parenchyma and therefore causes dyspnoea as
well as rapid loss of physical ﬁtness and quality of life [2].
Lung volume reduction surgery (LVRS) is a successful and well-
established palliative treatment for end-stage emphysema in care-
fully selected patients. Several randomized controlled trials have
conﬁrmed the feasibility of surgical therapy and that it is superior
to best medical treatment in long-term survival and exercise cap-
acity in a speciﬁc subgroup of patients [3–6].
The pathophysiology of severe emphysema includes hyper-
inﬂation and small airway obstruction through parenchymal
destruction, thereby allowing the possibility of mechanical repair.
By surgically removing the most affected areas of lung paren-
chyma, hyperinﬂation is reduced and diaphragm and chest wall
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mechanics are improved. Furthermore, small airway obstruction
can be reduced by an increase of elastic recoil forces [7].
The effects of LVRS may last for up to 5 years, depending on the
morphology of the emphysema [8, 9]. Surgery itself does not
modify the subsequent natural history of the disease [3] and, as
the natural history of emphysema and the annual decline in pul-
monary function take their course, lung function and dyspnoea
return to pre-LVRS levels after a certain period that differs from
person-to-person [4].
The only treatment that can stop the progressive course of the
disease is bilateral lung transplantation. In some patients, it may
be feasible to use LVRS as a bridge to transplantation [10–12];
however, many patients with end-stage COPD do not qualify for
transplantation because of advanced age or comorbidities, and
therefore LVRS has been described as a successful alternative in
appropriately selected patients [11, 13, 14].
Recent data from the Society of Thoracic Surgeons database
suggests a limited use of LVRS in the USA, with an initial increase
of LVRS performed after data from the National Emphysema
Treatment Trial were published but with numbers remaining
steady since 2004 [15]; data for Europe are, unfortunately, not
available, but again a limited use can be assumed. However, many
patients treated by LVRS survive the duration of the positive effect
and re-experience the loss of quality of life despite receiving
optimal medical treatment. For those not eligible for transplant-
ation, a limited range of therapeutic options remain.
Repeated LVRS (Re-LVRS) is a technically and also medically
challenging procedure that targets the ongoing parenchymal
destruction. Data regarding the feasibility and safety of Re-LVRS
are scarce. However, a ﬁrst case was described by Stammberger
et al. in 2000 [16], after which the beneﬁcial effects of Re-LVRS
on pulmonary function and quality of life were shown in a
small population of 16 patients [17]. However, while it was tech-
nically feasible and led to overall improvements, the reported
mortality rate was as high as 11.7%, rendering it a high-risk
operation [17].
The aim of this retrospective study was to further evaluate the
morbidity and mortality, as well as the efﬁcacy and outcome, due
to Re-LVRS in carefully selected patients after cessation of the
beneﬁcial effects of initial LVRS, to elucidate the role of repeated
surgery in this high-risk population.
MATERIALS ANDMETHODS
Patient selection
Inclusion criteria were adapted from our modiﬁed patient selec-
tion criteria for initial LVRS [7]. Patients eligible for Re-LRVS had to
have experienced a signiﬁcant improvement of dyspnoea and pul-
monary function test after the initial LVRS, but had to present with
a deterioration of their dyspnoea [measured by Medical Research
Council (MRC) dyspnoea score] and pulmonary function tests
(PFTs) to levels similar to the pre-LVRS level. In addition to severe
airﬂow obstruction (FEV1 < 35%), hyperinﬂation of the lung
(TLC > 120%, RV > 200%, RV/TLC > 65) and sustained minimum dif-
fusion capacity (DLCO > 20%), the patients selected for Re-LVRS
had to be highly motivated for a repeated operation.
CT scans had to reveal either heterogeneous to intermediately
distributed marked areas of emphysematous destruction, or newly
diagnosed intrapulmonary nodules suspicious for malignancy.
Patients with signiﬁcant comorbidities, like coronary artery disease
or pulmonary hypertension, were excluded.
Preoperative assessment
Prior to the operation, rigorous testing was performed to verify
operability. In addition to recent PFTs and chest CT scans with
densitometry, a radionuclide lung perfusion scan was performed
to identify the most affected areas. To further evaluate operability,
myocardial SPECT was performed in patients with uncertain myo-
cardial function (n = 7, 32%).
The MRC dyspnoea score, a simple and valid score that consists
of ﬁve categories (0–4), and which has been shown to correctly
categorize disability in COPD patients [18], was used to categorize
the physical disability of the patients due to COPD.
Decisions on reoperation were taken according to our inclu-
sion/exclusion criteria by an interdisciplinary committee consist-
ing of thoracic surgeons, pulmonologists and radiologists.
Surgery
Re-LVRS was performed unilaterally by video-assisted thoraco-
scopy surgery (VATS) in 19 patients, and in 3 patients by thora-
cotomy due to adhesions from the previous LVRS or infection; 1
patient had a bilateral Re-LVRS (Table 1). The areas of pulmonary
parenchyma exhibiting greatest destruction were resected using
standard staplers (COVIDIEN Endo GIA™ Ultra Universal, ETHICON
Echelon ENDOPATH™) without buttressing (for both, initial LVRS
and Re-LVRS).
Follow-up and outcome measures
All PFTs were performed using a standard body plethysmograph
and CO diffusion capacity (Zahn, Germany). The follow-up in-
cluded PFT and MRC dyspnoea score at baseline and 3 and 12
Table 1: Patient specifics
Age, years (IQR) Bilateral procedure (n) Unilateral procedure (n) Additional information (n)
Thoracoscopy Thoracotomy Thoracoscopy Thoracotomy
Initial LVRS 59 (55–67) 20 – 1 1 Suspicious nodule: 1
Re-LVRS 65 (62–72) – 1 19 2 Transplantation waiting list: 2
Suspicious nodules: 4
Elective cardiac surgery: 1
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months after surgery. The success of the procedure was judged by
(i) reduction of hyperinﬂation assessed by a decrease in residual
volume (RV), total lung capacity (TLC) and their ratio (RV/TLC),
(ii) increase in forced vital capacity (FVC), forced expiratory
volume in 1 s (FEV1) and diffusion capacity of the lung for carbon
monoxide (DLCO), and (iii) reduction of dyspnoea assessed by the
MRC score. Patients with suspected or proven malignancy had
regular CT scans for the cancer follow-up.
Complete data sets of PFT are available for 22 (100%), 21 (95%)
and 14 patients (64%) after LVRS and for 22 (100%), 11 (50%) and
9 patients (41%) after Re-LVRS at baseline, 3 and 12 months after
the operation, respectively.
Statistical analysis
All values are displayed as the mean ± standard error or median
and interquartile range (IQR), unless otherwise stated. Descriptive
statistical analysis was performed comparing perioperative mor-
bidity and duration of hospitalization. PFT at 3 and 12 months
after either LVRS or Re-LVRS were compared with baseline values
using a two-tailed paired samples t-test. For evaluation between
the LVRS and the Re-LVRS group the Wilcoxon matched-pair
signed-rank test was used for continuous variables and McNemar’s
test for categorical variables.
A P-value of <0.05 was determined as signiﬁcant (*), and
P < 0.001 as highly signiﬁcant (**). All data were produced using
SPSS (IBM Corp., Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY, USA: IBM Corp.). Graphs were plotted
using GraphPad Prism version 4.0c for Macintosh (GraphPad
Software, San Diego, CA, USA).
RESULTS
Between June 2002 and December 2013, 22 patients (9 females)
with a median age of 65 years (IQR: 62–72) underwent repeated
LVRS (Re-LVRS) for the following reasons: (i) cessation of the bene-
ﬁcial effects of initial LVRS only (n = 15); (ii) tissue-diagnosis and
treatment of newly diagnosed intrapulmonary nodules (n = 4); (iii)
as a bridge to transplantation (n = 2) or (iv) during elective cardiac
surgery (n = 1) (also see Table 1). The median time span between
initial and repeated LVRS was 60 months (range: 25–196). During
the same period (between June 2002 and December 2013) 303
patients underwent ﬁrst-time LVRS, which means that 7% of all
LVRS performed during this time were Re-LVRS.
The morphology of the emphysema for initial LVRS was hetero-
geneous in 17 patients (77%), intermediate in 3 patients (14%) and
homogeneous in 2 patients (9%) according to Weder et al. in 1997
[19]. CT morphology had changed in 2 patients from a markedly
heterogeneous to an intermediate type after initial LVRS. Initial
LVRS was performed mostly bilaterally including upper lobes
(n = 17, 77%), while Re-LVRS was performed unilaterally in all but
1 patient and lower lobes were operated on more frequently
(Table 2). In 14 patients (64%) the same lobe was operated, 6
patients had lung resections in a different lobe (27%), and 2
patients had resections in the same and a different lobe (9%).
Severe adhesions were signiﬁcantly more frequent in Re-LVRS
compared with initial LVRS (8 vs 2, P = 0.031) and no relevant
adhesions were present signiﬁcantly more often during initial
LVRS (18 vs 7, P = 0.001).
The perioperative and 90-day mortality rate was 0% (Table 3);
the ﬁrst patient died 15 months postoperatively. The median hos-
pitalization time was signiﬁcantly longer for Re-LVRS compared
Table 2: Operated lobes for initial LVRS and Re-LVRS. Numbers shown are absolute patient numbers.
Upper lobe Lower lobe Combined Middle lobe
Bilateral Unilateral Bilateral Unilateral 2 Ipsilateral >2 Bilateral
Left Right Left Right
Initial LVRS 15 – 2 1 – – – 4 –
Re-LVRS 1 3 6 – 5 2 4 – 1
Same lobe Different lobe Same + different lobes
Re-LVRS 14 6 2
Table 3: Hospitalization specifics and perioperative morbidity and mortality for initial LVRS and Re-LVRS
Initial LVRS Re-LVRS Wilcoxon matched-pair
signed-rank test (P-value)
Hospitalization time (IQR) 9 (8–14) 14 (11–19) 0.017
Drainage time (IQR) 6 (4–10) 11 (6–13) 0.050
McNemar’s test (P-value)
Overall complications, n (%) 10 (45) 17 (77) 0.092
Pulmonary complications 9 (41) 16 (73) 0.092
Prolonged air leak 8 (38) 14 (64) 0.180
Pneumothorax 1 (4.5) 2 (9) 1.0
Operative revision 2 (9) 7 (32) 0.125
Cardiac complications 1 (4.5) 2 (9) 1.0
Perioperative mortality 0 0 –
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with initial LVRS (14 days, IQR: 11–19 vs 9 days, IQR: 8–14,
P = 0.017). The overall complication rate was lower, though not
statistically signiﬁcant, for LVRS compared with Re-LVRS (45 vs
77%, P = 0.092). Prolonged air leak accounted for the most fre-
quent cause of morbidity in both groups but did not reach statis-
tical signiﬁcance (36 vs 64%, P = 0.092). Surgical revisions were
three times more frequent after Re-LVRS than after initial LVRS,
but did not reach statistical signiﬁcance (32 vs 9% patients,
P = 0.125). Other morbidities are summarized in Table 3.
Levels of pulmonary function and subjective dyspnoea at the
time of reoperation were similar to levels prior to the initial oper-
ation (Table 4). Pulmonary function tests and dyspnoea score
(MRC breathlessness scale) were assessed 3 and 12 months after
Re-LVRS, showing signiﬁcant overall improvement of lung function
with improved FEV1 (Fig. 1), improved diffusion capacity (Fig. 2),
reduction in hyperinﬂation assessed by RV/TLC (Fig. 3) as well as
reduced dyspnoea assessed by the MRC score (Fig. 4) both after
initial and Re-LVRS (see Table 4).
After Re-LVRS the mean increase in FEV1 was 25 and 12% from
baseline (absolute increase of 7 and 3.2% of the predicted value
corresponding to 0.18 and 0.18 l) at 3 months and 12 months, re-
spectively, compared with 62 and 29% (absolute increase of 17.2
and 8.2% of the predicted value corresponding to 0.5 and 0.24 l)
after initial LVRS (also see Fig. 1). The mean reduction in pulmon-
ary hyperinﬂation, assessed by the decrease in RV/TLC, was 8 and
13%, and 14 and 13% from the baseline at 3 and 12 months for
Re-LVRS and initial LVRS, respectively. LVRS thereby showed a
more pronounced increase of FEV1 (P = 0.022), reduction of
hyperinﬂation assessed by RV/TLC (P = 0.008) as well as a lower
MRC score (P = 0.033) when compared with Re-LVRS at 3 months.
These differences were not detectable at 12 months.
DISCUSSION
In this retrospective study, we evaluated the safety, feasibility and
effects of repeated LVRS (Re-LVRS) in 22 carefully selected patients.
The question of further treatment options after the beneﬁcial
effects of an initially successful LVRS have vanished is raised fre-
quently in clinical practice; even though LVRS seems to be broadly
underused in Europe as well as the USA, patient numbers are at
least stable [15]. As ongoing parenchymal destruction and the
natural course of the disease continue at individual rates, the time
span towards deterioration to initial exercise ability varies between
patients and emphysema type [9], but positive effects may last
for up to 5 years. After this individual time span the patients
Table 4: Pulmonary function tests before and 3 and 12 months after initial LVRS and Re-LVRS
Parameter Before initial LVRS 3 months after LVRS 12 months after LVRS Pre-Re-LVRS 3 months after Re-LVRS 12 months after Re-LVRS
FVC (l) 2.4 ± 0.13 3.32 ± 0.2** 2.98 ± 0.3** 2.4 ± 0.13 2.7 ± 0.14* 3.0 ± 0.3*
FVC (%) 69 ± 3.6 90.5 ± 3.7** 88.1 ± 6.5** 70 ± 4.4 80 ± 4.5* 82 ± 6.4*
FEV1 (l) 0.79 ± 0.05 1.3 ± 0.1** 1.03 ± 0.1* 0.72 ± 0.04 0.9 ± 0.06* 0.9 ± 0.1*
FEV1 (%) 27.8 ± 1.8 45 ± 3.0** 36 ± 3.5* 28.6 ± 3.0 34.8 ± 3.0* 31 ± 2.6*
RV (l) 5.55 ± 0.29 4.00 ± 0.2** 4.2 ± 0.3** 5.6 ± 0.3 4.2 ± 0.4* 4.2 ± 0.4
RV (%) 255 ± 12 181 ± 9.4** 185 ± 11** 237 ± 14 182 ± 22* 168 ± 28
TLC (l) 8.4 ± 0.3 7.7 ± 0.3* 7.8 ± 0.4* 7.7 ± 0.4 7.17 ± 0.4 7.4 ± 0.8
TLC (%) 138 ± 5 125 ± 3.2* 127 ± 3.4* 135 ± 5.1 118 ± 7.1* 112 ± 10
RV/TLC (%) 66 ± 2 52 ± 1** 53 ± 2** 68 ± 2 60 ± 3* 56 ± 3*
DLCO (%) 41 ± 2.4 48 ± 3.0 47 ± 2.7 35 ± 2.5 34 ± 2.2 41 ± 6
MRC scale [0–4] 3.3 ± 0.1 0.85 ± 0.2** 1.4 ± 0.26** 3.7 ± 0.1 2.2 ± 0.2* 1.0 ± 0.7
DLCO: diffusion capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; TLC: total
lung capacity
Mean ± standard error. *P < 0.05;
**P < 0.001 compared with preoperative values.
Figure 1: Course of FEV1 (% of predicted) preoperative (0), 3 and 12 months for
initial LVRS and Re-LVRS. *P < 0.05, **P < 0.001 for 3 and 12 months compared
with baseline. §P < 0.05 for LVRS vs Re-LVRS. FEV1: forced expiratory volume in
1 s.
Figure 2: Course of DLCO (% of predicted) preoperative (0), 3 and 12 months
for initial LVRS and Re-LVRS. Changes at 3 and 12 months not signiﬁcant com-
pared with baseline. §P < 0.05 for LVRS vs Re-LVRS. DLCO: diffusion capacity of
the lung for carbon monoxide.
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re-experience the loss of physical ﬁtness and quality of life and, for
those not eligible for transplantation, treatment options are very
limited.
Re-LVRS has so far been reported in a case report as well as in
one small retrospective study; beneﬁcial effects of Re-LVRS were
suggested in some patients [16, 17]. However, high mortality and
morbidity were reported, particularly due to the high-risk popula-
tion of end-stage emphysema patients in the setting of a reopera-
tion, with a higher incidence of ARDS in these patients compared
with the ﬁrst-time LVRS population [17].
In our cohort of 22 patients, the preoperative lung function
values had decreased to levels similar to that before the initial
LVRS, and repeated LVRS was performed after a median time of
60 months. Improvements in lung function after unilateral, thora-
coscopic Re-LVRS were statistically signiﬁcant compared with
baseline and showed a similar extent at 12 months compared with
the initial LVRS. However, beneﬁcial effects were more pro-
nounced after initial LVRS compared with Re-LVRS at 3 months.
The reduction in hyperinﬂation as well as subjective dyspnoea
was comparable with data published by Taccconi et al. [17].
Reoperations were technically feasible, and all but three were per-
formed by VATS. Not surprisingly, overall morbidity was lower
after the initial LVRS compared with Re-LVRS (operative revisions
were necessary three times more frequently in the latter; also see
Table 3), but these differences were not statistically signiﬁcant. The
complication rate stayed within an acceptable range and was
comparable with international data after LVRS [3–6, 15]. In contrast
to a previous report of Re-LVRS, we observed no perioperative
mortality or ARDS in our cohort.
The 90-day mortality rate of 0% may be explained, to some
extent, by rigorous selection of candidates and high surgical ex-
pertise (all operations were performed by the same surgeon
(Walter Weder) as well as anaesthesia and ICU management.
Other important factors include optimal medical treatment as well
as intensive physiotherapy and pulmonary rehabilitation pro-
grammes and a multidisciplinary approach [20].
Re-LVRS successfully treated the disabling dyspnoea in this
population of 22 patients; however, the small number of patients
and limited availability of complete data sets limit the validity of
this study to some extent. Moreover, the retrospective design may
have resulted in a selection bias. To shed more light on the ques-
tion of safety and efﬁcacy, prospective analysis of a bigger patient
population in a prospective manner is needed. However, this
small study proves that Re-LVRS is an option and should be con-
sidered in selected patients.
While small numbers limit the validity of the study as a whole,
each patient represents their own control group; ﬁrst, because they
had already proved to beneﬁt from LVRS due to the speciﬁc patho-
physiological mechanisms of their disease, and secondly, because
lung function had deteriorated to a pre-LVRS level despite adminis-
tration of optimal medical treatment. A repeated gain in lung func-
tion after Re-LVRS therefore may work by the same mechanisms as
initial LVRS and might be superior to the best medical treatment in
some patients. Hence, a previous LVRS should not be considered as
a contraindication to perform Re-LVRS and patients should be
selected according to the same criteria. For safety reasons and due
to the fact that DLCO was lower compared with the ﬁrst interven-
tion, we decided to perform Re-LVRS unilaterally only.
End-stage emphysema remains an incurable disease and no
medical treatment has been shown to inﬂuence the course of the
disease; therefore the only deﬁnitive treatment for patients previ-
ously treated by LVRS is lung transplantation. However, consider-
ing the limited donor availability and high mortality rates on the
waiting list [12], Re-LVRS can be considered as a bridge to trans-
plantation in younger patients and as a ﬁnal treatment in elderly
patients or those otherwise not eligible for transplantation.
In conclusion, our ﬁndings emphasize that Re-LVRS is safe to be
performed in carefully selected patients and may lead to signiﬁ-
cantly reduced dyspnoea and improved lung function for at least
12 months postoperatively. A previous LVRS should therefore not
be considered a contraindication for LVRS, and the same patient
selection criteria should be applied.
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